In the H-L and L–L categories, there was significant upregulation of tumour immunity and mammary stemness signatures, while markers of proliferation, HRD, TP53 surrogate mutational status, and ER-signalling were downregulated relative to those in the H–H group (Fig. 2c and Supplementary Figure S2). The gene discussed is TP53; the disease is neoplasm.